Akebia Therapeutics (AKBA) Misses Q4 EPS by 38c
Tweet
Share
E-mailGet Alerts AKBA Hot Sheet
Join SI Premium – FREE
Akebia Therapeutics (NASDAQ: AKBA) reported Q4 EPS of ($0.66), $0.38 worse than the analyst estimate of ($0.28).
For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- SPS Commerce hires Morgan Stanley to explore sale amid activist push - Reuters
- Nike names former Pfizer CFO David Denton as new finance chief
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
